Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

Condition:   Erosive Esophagitis Interventions:   Drug: DWP14012 Xmg;   Drug: DWP14012 Xmg placebo;   Drug: Esomeprazole 40mg;   Drug: Esomeprazole 40mg placebo Sponsor:   Daewoong Pharmaceutical Co. LTD. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials